侵袭性曲霉病的优效性试验：IA-DUET（HOVON502）试验的严峻现实检验
Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial.
作者信息
Lamberink Hanne, Huygens Sammy, Aerts Robina, Lagrou Katrien, van Leeuwen-Segarceanu Elena, Lodewyck Tom, Nieuwenhuizen Laurens, Corsten Maarten F, Moors Ine, Servais Sophie, De Greef Julien, Hites Maya, Demandt Astrid, Schauwvlieghe Alexander, Maertens Johan, Rijnders Bart
机构信息
Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Hematology, Ghent University Hospital, Ghent, Belgium.
出版信息
Clin Infect Dis. 2025 Feb 24;80(2):367-370. doi: 10.1093/cid/ciae501.
The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.
IA-DUET研究旨在比较唑类药物与棘白菌素联合治疗和唑类药物单药治疗侵袭性曲霉病的效果。患者不符合入选标准、存在竞争性研究以及在唑类药物耐药情况不明时指南倾向于联合治疗，这些因素阻碍了研究招募。侵袭性曲霉病所致的低死亡率表明，未来的试验可能会从整群随机化或复合终点中受益，以提高效率。
Zotero 插件